Gastrointestinal side effects are by far the most prevalent during early treatment: Nausea Very common (may affect more than 1 in 10 people), typically peaking during the first week and often improving over two to four weeks [1] [2] Vomiting Common (may affect up to 1 in 10 people), usually occurring alongside nausea [1] [2] Diarrhoea Common, may persist for several weeks Constipation Common, sometimes alternating with diarrhoea Abdominal pain or discomfort Common, ranging from mild cramping to more pronounced discomfort Dyspepsia (indigestion) Common Eructation (belching) Common Reduced appetite A therapeutic effect that may feel uncomfortable initially, affecting eating patterns These symptoms arise because semaglutide mimics the natural GLP-1 hormone, which slows gastric emptying and increases satiety
How PlexusDx Supports a More Personalized Approach PlexusDx Precision Peptide Genetic Testing identifies variants in GLP1R (rs6923761) and FTO (rs9939609) that may provide context for how individual patients metabolize glucose and respond to GLP-1-based therapies
In: Diabetologie kompakt, Blackwell Verlag Berlin, 2
As we age, our bodies naturally produce less glutathione, a vital molecule for maintaining good health
While the drugs themselves have potential benefits for some, modern telehealth companies in a bid to sell to all are weaponizing language around health and medicalizing insecurity to turn a profit
A systematic review examining studies on BPC-157 and musculoskeletal healing found that the vast majority were preclinical (primarily conducted in rats), with very limited clinical data in humans
